Preparation of tolerance nanoparticles for the treatment of primary biliary cholangitis
Tolerance-modified immunomodulatory nanoparticles encapsulating PBC antigens address the challenge of immune activation in PBC treatment by ensuring safe and effective antigen delivery, enhancing therapeutic efficacy.
JP2026519487APending Publication Date: 2026-06-16COUR PHARMA DEV CO INC
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- COUR PHARMA DEV CO INC
- Filing Date
- 2024-05-23
- Publication Date
- 2026-06-16
AI Technical Summary
Technical Problem
Current treatments for primary biliary cholangitis (PBC) do not effectively induce antigen-specific immune tolerance, leading to immune activation and lack of therapeutic efficacy.
Method used
The development of tolerance-modified immunomodulatory nanoparticles (TIMP-PBC) encapsulating PBC-associated antigens, manufactured through a process involving emulsion formation and curing, ensures safe and effective delivery of antigens to APCs without inducing immune activation.
Benefits of technology
The process enables efficient encapsulation of PBC antigens within nanoparticles, promoting antigen-specific immune tolerance and providing a therapeutic solution for PBC.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 2026519487000003 
Figure 2026519487000004 
Figure 2026519487000005
Abstract
The process for manufacturing TIMP-PBC involves numerous steps, each of which affects the physicochemical properties of the resulting composition, which are essential for safe and therapeutic administration. [Solution] This disclosure relates to a process for preparing tolerance-modifying immunomodulatory nanoparticles encapsulating antigens associated with primary biliary cholangitis (PBC) for the treatment of PBC, a composition comprising such particles, and the use thereof.
Need to check novelty before this filing date? Find Prior Art